SLRN - ACELYRIN, Inc.

2.27
0.040   1.762%

Share volume: 4,076,542
Last Updated: 05-20-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$2.23
0.04
0.02%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 20%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
-6.20%
3 Months
-14.66%
6 Months
-46.59%
1 Year
-46.59%
2 Year
-86.73%
Key data
Stock price
$2.27
P/E Ratio 
0.00
DAY RANGE
$2.20 - $2.36
EPS 
-$2.56
52 WEEK RANGE
$1.84 - $7.25
52 WEEK CHANGE
-$49.10
MARKET CAP 
248.753 M
YIELD 
N/A
SHARES OUTSTANDING 
100.954 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
1.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
$1,449,904
Company detail
CEO: Shao-Lee Lin
Region: US
Website: acelyrin.com
Employees: 0
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ACELYRIN is a late-stage clinical biopharma company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. Our principal executive offices are located at 4149 Liberty Canyon Road, Agoura Hills, California.

Recent news